게시일

This updated guidance from the Infectious Diseases Society of America (IDSA) aims to provide an evidence-based diagnostic guideline to assist clinicians, clinical laboratorians, patients and policymakers in decisions related to the optimal use of COVID-19 molecular diagnostic testing.

IDSA guidelines on the diagnosis of COVID-19 molecular diagnostic testing

en

Infectious Diseases Society of America (IDSA), 2020

This updated guidance from the Infectious Diseases Society of America (IDSA) aims to provide an evidence-based diagnostic guideline to assist clinicians, clinical laboratorians, patients and policymakers in decisions related to the optimal use of COVID-19 molecular diagnostic testing.

In addition, a conceptual framework for understanding molecular diagnostic test performance is provided, plus the authors discuss test result interpretation in different practice settings. The guidance highlights that universal access to accurate testing is critical for patient care, hospital infection prevention and the public response to the COVID-19 pandemic.

The IDSA panel weigh available diagnostic evidence and make recommendations for nucleic acid testing for all symptomatic individuals suspected of having COVID-19. In addition, testing is recommended for asymptomatic individuals with known or suspected contact with a COVID-19 case. Testing asymptomatic individuals without known exposure is suggested when the results will impact isolation / quarantine / personal protective equipment usage decisions, dictate eligibility for surgery, or inform solid organ or hematopoietic stem cell transplantation timing.

Of note, the guidance highlights that rapid point-of-care testing requires less operator steps compared with standard tests that require instrumentation and/or processing that must be performed in a clinical laboratory by trained laboratory staff.

The guidelines can be accessed here.

COL-08886 10/2021

관련 뉴스

Cards

  • 게시일

    Kunihiro Matsushita, Josef Coresh, Yingying Sang, John Chalmers, Caroline Fox, Eliseo Guallar, Tazeen Jafar, Simerjot K Jassal, Gijs W D Landman, Paul Muntner, Paul Roderick, Toshimi Sairenchi, Ben Schöttker, Anoop Shankar, Michael Shlipak, Marcello Tonelli, Jonathan Townend, Arjan van Zuilen, Kazumasa Yamagishi, Kentaro Yamashita, Ron Gansevoort, Mark Sarnak, David G Warnock, Mark Woodward, Johan Ärnlöv, CKD Prognosis Consortium

    Estimated glomerular filtration rate and albumin-to-creatinine ratio testing for cardiovascular risk assessment

    en
    지금 액세스
    Restricted
  • 게시일

    Johan Sundström, Johan Bodegard, Andreas Bollmann, Marc G Vervloet, Patrick B Mark, Avraham Karasik, Tiago Taveira-Gomes, Manuel Botana, Kåre I Birkeland, Marcus Thuresson, Levy Jäger, Manish M Sood, Gijs VanPottelbergh, Navdeep Tangri; on behalf of the CaReMe CKD Investigators

    Prevalence, outcomes and cost of chronic kidney disease

    en
    지금 액세스
    Restricted
  • 게시일

    Marleen Smits, Rogier Hopstaken, Lusan Terhaag, Gijs de Kort, Paul Giesen

    HbA1c and glucose point‑of‑care testing in general practice

    en
    지금 액세스
    Restricted